Compare BioNano Genomics Inc (BNGO) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Equinix Inc — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while Equinix Inc trades at $1,065.67 (market cap $101.87B). The key difference: Equinix Inc is far larger — about 7457.5× BioNano Genomics Inc's market cap, and Equinix Inc pays a 2% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | EQIX | |
|---|---|---|
Market Cap | $13.66M | $101.87B |
Sector | Health | Real Estate |
52-Week High | $4.92 | $1.12K |
52-Week Low | $1.06 | $726.09 |
Enterprise Value | $16.26M | $123.00B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
Equinix (EQIX) trades at $1,049.99, up 0.63% today, with a neutral technical signal as it hovers near resistance at $1,050. The stock shows strong analyst support (74.51% buy ratings) and a consensus price target of $1,120, driven by robust revenue growth, expanding net income margins to 15.63% in 2025, and positive news on AI infrastructure demand. However, high valuation ratios like a P/E of 66.44 and significant capital expenditures pose challenges.
The outlook remains positive due to sustained digital infrastructure demand and raised long-term guidance, but risks include elevated debt levels and earnings misses in recent quarters. Investors should weigh growth prospects against premium valuations and cash flow pressures from heavy investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
